目的:探讨在化疗基础上联合康莱特注射液在肺腺癌患者中应用对肿瘤标志物、血管新生和免疫球蛋白指标水平的影响。方法:选取就诊于我院及无锡市第五人民医院的肺腺癌患者88例,按入院顺序随机分组,观察组和对照组均为44例,观察组予以化疗+康莱特注射液治疗,对照组仅予以化疗,3周为一疗程,两个疗程后比较两组癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原199(CA199)、血管内皮因子-A(VEGFA)、血管内皮因子-B(VEGFB)、血管内皮因子-C(VEGFC)以及粘膜免疫分泌抗体(IgA)、初次免疫反应抗体(IgM)、再次免疫反应抗体(IgG)水平。结果:两组治疗前CEA、CA125、CA199水平相持平,差异无统计学意义(P＞0.05),观察组治疗后CEA水平低于对照组,差异具有统计学意义(P<0.05),治疗后CA125和CA199水平虽有降低,但较治疗前及两组间差异均无统计学意义(P＞0.05)；两组治疗前VEGFA、VEGFB和VEGFC水平相持平,差异无统计学意义(P＞0.05),观察组治疗后VEGFA水平低于对照组,差异具有统计学意义(P<0.05),治疗后VEGFB和VEGFC水平虽均有所降低,但较治疗前及两组间差异均无统计学意义(P＞0.05)；两组治疗前IgA、IgM和IgG水平相持平,差异无统计学意义(P＞0.05),观察组治疗后IgM水平高于对照组,差异具有统计学意义(P<0.05),IgA和IgG水平在治疗后均有所升高,但较治疗前及两组间差异均无统计学意义(P＞0.05)；两组治疗后均未发生严重不良反应。结论:康莱特注射液联合化疗在肺腺癌患者中应用可下调肿瘤标志物水平,有效抑制肿瘤血管新生,增强机体免疫力,推荐临床应用。

Objective: To explore the effect of Kanglaite injection combined with chemotherapy on the levels of tumor factors, angiogenesis and immunoglobulin in patients with lung adenocarcinoma. Method: A total of88 patients with lung adenocarcinoma in our hospital and the Fifth People's Hospital of Wuxi from February 2014 to December 2017 were divided randomly into observation group and control group according to the admission time, 44 cases for each group. The observation group was treated with chemotherapy combined with Kanglaite injection, and the control group was treated with chemotherapy only.Both groups were treated for 6 weeks. The levels of CEA, CA125, CA199, VEGFA, VEGFB, VEGFC, and IgA, IgM, IgG after treatment in both groups were compared. Result: Before treatment, there were no significant differences inthe levels of CEA, CA125 and CA199 between two groups (P>0.05). The level of CEA in the observation group (29.88 ±7.07) μ g / L was lower than that in the control group,and the difference was statistically significant (P<0.05). The levels of CA125 and CA199 after treatment were lower than those before treatment, but with no significant difference (P>0.05). Between the two groups,there was no significant difference in the levels of VEGFA,VEGFB and VEGFC before treatment (P>0.05). The level of VEGFA after treatment in the observation group (80.49 ±12.29) ng/mL was lower than that in the control group and the difference was statistically significant (P<0.05). However, the levels of VEGFB and VEGFC after treatment were also lower than those before treatment, but with no significant difference (P>0.05). Moreover, the levels of IgA, IgM and IgG before treatment in two groups had no significant difference (P>0.05). The level of IgM after treatment in the observation group (1.52±0.30)g/L was higher than that in the control group, with a statistically significant difference (P<0.05). The levels of IgA and IgG after treatment were higher than those before treatment, but with no significant difference (P>0.05); No serious adverse reaction was observed after treatment in both groups. Conclusion: Kanglaite injection combined with chemotherapy has a good clinical effect in lung adenocarcinoma, which can effectively inhibit the high expression of tumor markers, reduce angiogenesis, and enhance body immunity, thus it can be recommended for clinical application.

R734.2

江苏省卫生厅重点学科省内开放课题(KF201512)